Cema-cel for high-risk lymphoma after first treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these types of lymphoma: diffuse large B-cell, high-grade B-cell, or primary mediastinal B-cell lymphoma.
- You must have completed a full course of standard first-line treatment (like R-CHOP or similar) and not received any other treatments.
- After your first treatment, your PET/CT scan must show that you are in complete remission or have a partial remission that is safe to watch.
- A special blood test (Foresight CLARITY MRD) must find tiny amounts of cancer cells left in your body.
- You must be 18 years or older, in good overall health (ECOG 0 or 1), and have adequate organ function.
- You cannot have had any prior treatment that targets CD19, or have active autoimmune disease, serious infections, or another cancer in the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
This trial tests whether a drug called emapalumab can reduce serious side effects from CAR-T cell therapy, a treatment for large B-cell lymphoma that has come back or not responded to earlier treatments. If you qualify, you would receive emapalumab alongside your CAR-T treatment to help make it safer.
This trial tests a new drug called epcoritamab for people whose large B-cell lymphoma has come back after or didn't fully respond to their first treatment. It's an option for those who cannot or choose not to have CAR-T therapy or a stem cell transplant.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This trial tests a one-time cell therapy (your own immune cells are modified to attack the lymphoma) as the first treatment for high-risk large B-cell lymphoma. It aims to see if this approach is safe and effective for people whose cancer is not responding well to initial chemotherapy.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.